- Home
- TKLF vs NRSN Comparison
TKLF vs NRSN Comparison
Compare TKLF & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKLF
- NRSN
- Stock Information
- Founded
- TKLF 2006
- NRSN 2017
- Country
- TKLF Japan
- NRSN Israel
- Employees
- TKLF N/A
- NRSN N/A
- Industry
- TKLF Other Specialty Stores
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- TKLF Consumer Discretionary
- NRSN Health Care
- Exchange
- TKLF Nasdaq
- NRSN Nasdaq
- Market Cap
- TKLF 18.5M
- NRSN 17.8M
- IPO Year
- TKLF 2022
- NRSN 2021
- Fundamental
- Price
- TKLF $3.47
- NRSN $1.14
- Analyst Decision
- TKLF
- NRSN Hold
- Analyst Count
- TKLF 0
- NRSN 1
- Target Price
- TKLF N/A
- NRSN N/A
- AVG Volume (30 Days)
- TKLF 45.4K
- NRSN 360.5K
- Earning Date
- TKLF 12-18-2024
- NRSN 12-31-2024
- Dividend Yield
- TKLF N/A
- NRSN N/A
- EPS Growth
- TKLF N/A
- NRSN N/A
- EPS
- TKLF 2.01
- NRSN N/A
- Revenue
- TKLF $195,681,315.00
- NRSN N/A
- Revenue This Year
- TKLF N/A
- NRSN N/A
- Revenue Next Year
- TKLF N/A
- NRSN N/A
- P/E Ratio
- TKLF $1.85
- NRSN N/A
- Revenue Growth
- TKLF 15.29
- NRSN N/A
- 52 Week Low
- TKLF $2.00
- NRSN $0.51
- 52 Week High
- TKLF $10.00
- NRSN $2.33
- Technical
- Relative Strength Index (RSI)
- TKLF 44.96
- NRSN 56.63
- Support Level
- TKLF $3.54
- NRSN $0.80
- Resistance Level
- TKLF $3.95
- NRSN $1.29
- Average True Range (ATR)
- TKLF 0.30
- NRSN 0.13
- MACD
- TKLF 0.07
- NRSN 0.01
- Stochastic Oscillator
- TKLF 40.45
- NRSN 68.75
About TKLF Yoshitsu Co. Ltd
Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores; Online Stores and Services; and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from China followed by Japan and other overseas markets.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.